Filing Details
- Accession Number:
- 0001209191-22-006362
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-02 16:17:25
- Reporting Period:
- 2022-01-31
- Accepted Time:
- 2022-02-02 16:17:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1438533 | Travere Therapeutics Inc. | TVTX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1388773 | Laura Clague | C/O Travere Therapeutics, Inc. 3611 Valley Centre Dr., Suite 300 San Diego CA 92130 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-01-31 | 9,840 | $0.00 | 39,093 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2022-01-31 | 1,238 | $27.40 | 37,855 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee stock option (right to buy) | Acquisiton | 2022-01-31 | 39,360 | $0.00 | 39,360 | $27.50 |
| Common Stock | Performance-based restricted stock units | Acquisiton | 2022-01-31 | 9,840 | $0.00 | 9,840 | $0.00 |
| Common Stock | Performance-based restricted stock units | Acquisiton | 2022-01-31 | 8,000 | $0.00 | 8,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 39,360 | 2032-01-30 | No | 4 | A | Direct | |
| 9,840 | No | 5 | A | Direct | ||
| 8,000 | No | 5 | A | Direct |
Footnotes
- Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.
- The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
- Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.
- This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.
Billionaire Hedge Funds
